华东医药：2025年半年度报告（英文版）.pdf

1、Full text of the 2025 Semi-annual Report of Huadong Medicine Co.,Ltd.1Huadong Medicine Co.,Ltd.2025 Semi-annual ReportAugust 20,2025Full text of the 2025 Semi-annual Report of Huadong Medicine Co.,Ltd.2Section I Important Notes,Table of Contents and DefinitionsThe Board of Directors,directors,and se

2、nior management of HuadongMedicine Co.,Ltd.(hereinafter referred to as the Company)herebyguarantee that the information presented in this report is authentic,accurateand complete,and free of false records,misleading statements or materialomissions,and shall undertake individual and joint legal liabi

3、lities.Lv Liang,the Companys legal representative and the officer in charge ofaccounting,and Qiu Renbo,head of the accounting department(accountingmanager)hereby declare that the financial statements in this semi-annualreport are authentic,accurate,and complete.All directors have attended the Board

4、of Directors meeting to review thissemi-annual report.The future plans,development strategies and other forward-lookingstatements in this semi-annual report shall not be considered as a substantialcommitment of the Company to investors.Investors and related parties shouldbe fully aware of the risks,

5、and understand the differences between plans,forecasts and commitments.The risks the Company faces in operation include industry policy andproduct price reduction risk,new drug R&D risk,investment and M&A riskand exchange rate fluctuation risk.For details,please refer to X.Risks facedby the Company

6、and countermeasures in Section III.ManagementsDiscussion and Analysis.Therefore,investors are kindly reminded to payattention to possible investment risks.Full text of the 2025 Semi-annual Report of Huadong Medicine Co.,Ltd.3The dividend distribution scheme approved at the meeting of the Board ofDir